GEN Exclusives

More »

GEN News Highlights

More »
Oct 24, 2007

Noven's Stavzor Closer to Being Commercialized with Receipt of FDA Approvable Letter

  • Noven Pharmaceuticals received a letter from the FDA for its drug related to bipolar disorder stating that while approvable, the agency requires more nonclinical information.

    Among the additional information requested is in vitro dissolution data, according to Noven. The FDA has not requested additional human studies or clinical data, the company adds.

    The letter is related to Stavzor™ in 125 mg, 250 mg, and 500 mg strengths. If approved, the drug will be indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

    Because the NDA for Stavzor references Abbott Laboratories' Depakote® product, final approval is also subject to the expiration of any applicable exclusivity periods benefiting Depakote. Noven thus expects Stavzor final approval at the latest by the end of July 2008.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »